Navigation Links
MRI may be noninvasive method to measure breast cancer prognosis
Date:12/8/2011

SAN ANTONIO Quantitative magnetic resonance imaging measures were associated with prognostic tumor markers, demonstrating the potential of magnetic resonance imaging for prediction of disease prognosis and stratification of patients to appropriate therapies, according to preliminary data presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 6-10, 2011.

"Breast cancers are heterogeneous, and different subtypes of breast cancer will respond differently to therapy," said Sana Parsian, M.D., a research assistant in the department of radiology at the University of Washington in Seattle. "Every patient with breast cancer must undergo biopsy to be evaluated for the type of breast cancer they have. Based on that, adjuvant medical therapies are prescribed for them."

Parsian and her colleagues hypothesized that some quantitative magnetic resonance imaging (MRI) measures, such as diffusion-weighted MRI (DWI) and dynamic contrast-enhanced MRI (DCE), would correlate with histopathological markers by enabling the researchers to measure the tumor's cellularity and vascularity.

In DWI, the diffusion of fluids along a field gradient reduces the MRI signal, so it can determine cellularity of the tumor by measuring the degree of water mobility. DCE enables viewers to see more information about tumor vascularity. A malignant cell group needs a blood supply to grow, and those vascular changes cause tumors to appear differently on DCE compared with normal tissue, Parsian said. The enhancement pattern seen on an MRI is called kinetics.

Researchers evaluated correlations between DWI and DCE kinetics and histopathologic markers of breast cancer determined from biopsy, such as estrogen receptor (ER), progesterone receptor, HER2, p53 and the ki67 proliferation marker, in 41 invasive cancers among 36 patients. They found statistically significant correlations between MRI measures and all markers, except ER, which was only marginally associated with one of the DCE measures. Each of the DCE kinetics parameters significantly discriminated grade III tumors from grades I and II and luminal A from luminal B and basal-like intrinsic subtypes.

"When we looked at these measures, we realized there was a correlation with biomarkers," Parsian said.

Although these are preliminary data, she hopes that someday MRI might provide valuable noninvasive information about tumor biology for selecting and guiding targeted therapies.

Parsian said larger prospective studies are needed to confirm these results and that MRI may complement biopsy to sample the whole tumor and reflect tumor heterogeneity.

"I think the final goal of radiology is to get more information while doing the least amount of intervention possible for the patient," she said. "It would be great if we could improve our understanding of breast cancer biology and predict response to different therapies with imaging. Our study suggests MRI may play a valuable role in this process."


'/>"/>

Contact: Jeremy Moore
Jeremy.Moore@aacr.org
215-446-7109
American Association for Cancer Research
Source:Eurekalert

Related biology news :

1. Frost & Sullivan Recognizes AOptix Technologies for its Pioneering Contribution to Security through Noninvasive Biometrics
2. Star Trek-like technology offers noninvasive monitor for patients and athletes
3. Humble garden pea helps Kew scientists develop cool, noninvasive diagnostic test of seed quality
4. Cheap, simple, noninvasive blood test may replace invasive diagnostic techniques in early pregnancy
5. Noninvasive MR imaging of blood vessel growth in tumors using nanosized contrast agents
6. Auxogyn licenses noninvasive embryo assessment technology from Stanford University
7. Noninvasive wireless near-infrared device provides reliable diagnosis of bladder dysfunction
8. Noninvasive current stimulation improves sight in patients with optic nerve damage
9. Commercial aquatic plants offer cost-effective method for treating wastewater
10. UC Riverside biochemists devise method for bypassing aluminum toxicity effects in plants
11. New lab manual focuses on essential methods for purifying and characterizing proteins
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2016)... The Department of Transport Management (DOTM) of ... project, for the , Supply and Delivery of ... Infrastructure , to Decatur , ... Management Solutions. Numerous renowned international vendors participated in the tendering ... selected for the most compliant and innovative solution. The contract ...
(Date:5/24/2016)... , May 24, 2016 Ampronix facilitates superior patient care by providing unparalleled ... medical LCD display is the latest premium product recently added to the range of ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/9/2016)... May 9, 2016 Elevay is ... to expanding freedom for high net worth professionals seeking ... today,s globally connected world, there is still no substitute ... ever duplicate sealing your deal with a firm handshake. ... by taking advantage of citizenship via investment programs like ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
(Date:6/23/2016)... ... ... STACS DNA Inc., the sample tracking software company, today announced that Dr. Hays ... DNA as a Field Application Specialist. , “I am thrilled that Dr. Young ... DNA. “In further expanding our capacity as a scientific integrator, Hays brings a wealth ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... 2016 Andrew D ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... from touchONCOLOGY, Andrew D Zelenetz , discusses ... care is placing an increasing burden on healthcare ... therapies. With the patents on many biologics expiring, ...
Breaking Biology Technology: